Bivalent HPV Vaccine - Best Value For Money

Published Jun 17, 2012

Taipei, Taiwan - Cervical cancer (CC) is among the leading cancers in Taiwanese women of all, suggesting a need for prevention beyond current screenings.

Oncogenic human papillomavirus (HPV) has been identified as the primary causal agent for CC. Two HPV vaccines are available; both are good value for money when compared to screening alone. The preferable choice for mass vaccination from a health economic perspective remains to be determined. A recent study published in Value in Health, “Cost-Effectiveness Analysis of the Bivalent Compared to the Quadrivalent Human Papillomavirus Vaccine in Taiwan,” uses a cohort model to compare the two vaccines. The bivalent vaccine is estimated to avert 29% more CC cases and deaths compared with the quadrivalent vaccine due to its protection beyond vaccine types. This results in an additional economic and health benefit which outweigh the additional benefit of genital warts prevention from the quadrivalent vaccine. “Both vaccines have the potential to protect Taiwanese women against CC,” says Nadia Demarteau, lead author of the study. “However in the Taiwanese setting, our results indicate that using the bivalent vaccine provides more value for money.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×